ES2714350T3 - Tetrahidrocannabivarina (THCV) para uso en la protección de células del islote pancreático - Google Patents

Tetrahidrocannabivarina (THCV) para uso en la protección de células del islote pancreático Download PDF

Info

Publication number
ES2714350T3
ES2714350T3 ES15185536T ES15185536T ES2714350T3 ES 2714350 T3 ES2714350 T3 ES 2714350T3 ES 15185536 T ES15185536 T ES 15185536T ES 15185536 T ES15185536 T ES 15185536T ES 2714350 T3 ES2714350 T3 ES 2714350T3
Authority
ES
Spain
Prior art keywords
thcv
phytocannabinoid
tetrahydrocannabivarine
insulin
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15185536T
Other languages
English (en)
Spanish (es)
Inventor
Michael Cawthorne
Colin Stott
Stephen Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GW Pharma Ltd
Original Assignee
GW Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GW Pharma Ltd filed Critical GW Pharma Ltd
Application granted granted Critical
Publication of ES2714350T3 publication Critical patent/ES2714350T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES15185536T 2011-11-21 2012-11-20 Tetrahidrocannabivarina (THCV) para uso en la protección de células del islote pancreático Active ES2714350T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1120066.4A GB2496687A (en) 2011-11-21 2011-11-21 Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells

Publications (1)

Publication Number Publication Date
ES2714350T3 true ES2714350T3 (es) 2019-05-28

Family

ID=45475480

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12795839.5T Active ES2560835T3 (es) 2011-11-21 2012-11-20 Tetrahidrocannabivarina (THCV) para usar en la protección de células del islote pancreático
ES15185536T Active ES2714350T3 (es) 2011-11-21 2012-11-20 Tetrahidrocannabivarina (THCV) para uso en la protección de células del islote pancreático

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12795839.5T Active ES2560835T3 (es) 2011-11-21 2012-11-20 Tetrahidrocannabivarina (THCV) para usar en la protección de células del islote pancreático

Country Status (14)

Country Link
US (1) US20160243075A2 (enExample)
EP (2) EP2782568B1 (enExample)
JP (1) JP6338531B2 (enExample)
CN (1) CN103945841A (enExample)
AU (1) AU2013201809B2 (enExample)
BR (1) BR112014012159A2 (enExample)
CA (1) CA2856102A1 (enExample)
DK (1) DK2782568T3 (enExample)
ES (2) ES2560835T3 (enExample)
GB (2) GB2496687A (enExample)
MX (1) MX348564B (enExample)
PL (1) PL2782568T3 (enExample)
PT (1) PT2782568E (enExample)
WO (1) WO2013076471A1 (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US10774288B2 (en) 2013-09-18 2020-09-15 The Werc Shop, LLC Terpene-based compositions, processes, methodologies for creation and products thereby
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
IL258821B (en) 2015-10-23 2022-07-01 Harvard College Nucleobase editors and their uses
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
KR20250103795A (ko) 2016-08-03 2025-07-07 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 아데노신 핵염기 편집제 및 그의 용도
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
JP7588390B2 (ja) 2016-10-14 2024-11-22 プレジデント アンド フェローズ オブ ハーバード カレッジ 核酸塩基エディターのａａｖ送達
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
BR112019019655A2 (pt) 2017-03-23 2020-04-22 Harvard College editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
WO2019232740A1 (zh) * 2018-06-07 2019-12-12 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
CN110575447B (zh) * 2018-06-07 2022-11-29 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
US20220142985A1 (en) * 2018-08-10 2022-05-12 Servicio Andaluz De Salud Agents for treatment of alcohol use disorder
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
BR112021009021A2 (pt) * 2018-11-09 2021-10-26 Agriculture Victoria Services Pty Ltd Plantas de cannabis com um perfil canabinoide enriquecido de canabidiol e delta-9-tetra-hidrocanabinol
EP3942042A1 (en) 2019-03-19 2022-01-26 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP4188363A4 (en) 2020-07-28 2024-10-16 Wsmef, Llc FULL-SPECTRUM HEMP OIL MICELLE PREPARATIONS FOR THE TREATMENT OF TYPE II DIABETES, REDUCING INFLAMMATION DURING COVID-19 AND IMPROVING SLEEP QUALITY
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
CN113135885A (zh) * 2021-04-07 2021-07-20 上海同田生物技术有限公司 一种高速逆流色谱分离纯化四氢次大麻酚的方法
US12011470B2 (en) 2021-07-28 2024-06-18 Clint Sorensen Micelle preparations of full-spectrum hemp oil
WO2024006896A1 (en) * 2022-06-29 2024-01-04 The Regents Of The University Of California Uses of hydrogenated cannabidiol (h4cbd) and advanced metabolic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
KR20070089151A (ko) * 2004-11-16 2007-08-30 지더블유 파마 리미티드 카나비노이드의 새로운 용도
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
WO2007032962A2 (en) * 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
JP5072848B2 (ja) * 2005-09-20 2012-11-14 ノバルティス アーゲー 低血糖イベントを低減するためのｄｐｐ−ｉｖ阻害剤の使用
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen

Also Published As

Publication number Publication date
CA2856102A1 (en) 2013-05-30
BR112014012159A2 (pt) 2017-05-30
EP3028697A1 (en) 2016-06-08
CN103945841A (zh) 2014-07-23
US20140335208A1 (en) 2014-11-13
JP2014533680A (ja) 2014-12-15
GB201220874D0 (en) 2013-01-02
GB2496761A (en) 2013-05-22
US20160015682A2 (en) 2016-01-21
AU2013201809B2 (en) 2015-04-23
WO2013076471A1 (en) 2013-05-30
EP3028697B1 (en) 2018-12-26
DK2782568T3 (en) 2016-02-08
AU2013201809A1 (en) 2013-06-06
EP2782568B1 (en) 2015-10-28
ES2560835T3 (es) 2016-02-23
PT2782568E (pt) 2016-02-01
MX348564B (es) 2017-06-20
MX2014006057A (es) 2014-08-21
GB201120066D0 (en) 2012-01-04
PL2782568T3 (pl) 2016-05-31
US20160243075A2 (en) 2016-08-25
EP2782568A1 (en) 2014-10-01
JP6338531B2 (ja) 2018-06-06
GB2496687A (en) 2013-05-22

Similar Documents

Publication Publication Date Title
ES2714350T3 (es) Tetrahidrocannabivarina (THCV) para uso en la protección de células del islote pancreático
Yerevanian et al. Metformin: mechanisms in human obesity and weight loss
Christiansen et al. The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon
Cernea et al. Pharmacological management of glucose dysregulation in patients treated with second-generation antipsychotics
Wang et al. Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis
Kashani et al. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression
Li et al. Butyrate alleviates metabolic impairments and protects pancreatic β cell function in pregnant mice with obesity
Ruz et al. Zinc as a potential coadjuvant in therapy for type 2 diabetes
Thulé Mechanisms of current therapies for diabetes mellitus type 2
Papaetis Incretin-based therapies in prediabetes: current evidence and future perspectives
Cunha et al. Long-term effects of overfeeding during lactation on insulin secretion—the role of GLUT-2
Lin et al. Chronic pancreatitis and diabetes mellitus
Papaetis Liraglutide therapy in a prediabetic state: rethinking the evidence
Salehsari et al. Investigating the effect of zeaxanthin on olanzapine-induced metabolic disorders in rats
Rotondo et al. Randomised clinical trial: the DPP‐4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon‐like peptide‐1 plasma levels in healthy volunteers
Liberini et al. Liraglutide pharmacotherapy reduces body weight and improves glycaemic control in juvenile obese/hyperglycaemic male and female rats
Kautzky-Willer et al. Obesity and diabetes
Ertek et al. Is there U-turn from Insulin Back to Pills in Diabetes?
Sharifinejad et al. An Update on the Anti-diabetic Functions of Genistein: A Soybean (Glycine max (L.) Merr.) Isoflavone
García Cantú et al. Effects of liraglutide on weight reduction and metabolic parameters in obese patients with and without type 2 diabetes mellitus
US20150037361A1 (en) Compositions and methods to treat the bihormonal disorder in diabetes
Padhye et al. Effect of turmeric on alloxan induced diabetes mellitus in albino rats
Swetha et al. A Comparative Review Of Drugs And Dosage Form Used In Diabetes Mellitus With Future Aspects.
Munna Pharmacological Evaluation of Methanolic Extract of Nigella sativa on Hyperglycemia in Laboratory Animal Models
VIEIRA et al. THE LIRAGLUTIDE USE IN THE TREATMENT OF TYPE TWO DIABETES AND OBESITY: LITERATURE REVIEW.